Gene therapy to prevent vision loss: Studies in primates needed to optimize human trials

December 29, 2016
Credit: Mary Ann Liebert, Inc., publishers

Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy.

A team of researchers led by Jean Bennett, Scheie Eye Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, evaluated and compared two adeno-associated virus (AAV) vectors designed to deliver therapeutic genes directly to the eye when administered via subretinal injection to . They report the differences in gene expression efficiency and immunogenicity across different doses in the article entitled "Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-human Primate Retina."

Gene therapies developed and tested in mice may present quite different safety and efficacy profiles when administered to humans. Evaluating gene delivery vectors in non-human primates provides results that are more predictive of what one can expect in humans.

"Dr. Bennett and her team have already made major breakthroughs in gene therapy for genetic causes of blindness. The work published here promises to greatly improve the technology for ocular ," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA.

Explore further: New gene therapy strategies emerging to combat vision loss

More information: Pavitra S. Ramachandran et al, Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina, Human Gene Therapy (2016). DOI: 10.1089/hum.2016.111

Related Stories

New gene therapy strategies emerging to combat vision loss

June 22, 2016

Diseases of the eye that cause vision loss and blindness, especially neurodegenerative disorders affecting the retina, are ideal targets for gene therapy, including gene replacement and promising corrective gene editing strategies. ...

Recommended for you

Epigenetic factors linked to obesity-related disease

January 17, 2017

Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications ...

Are you ready to explore baby's genome?

January 17, 2017

When you have a baby, a nurse or a phlebotomist performs a heel stick to take a few drops of blood from your infant and sends it off to a state lab for a battery of tests. Most of the time, you never hear about the results ...

Study applies game theory to genomic privacy

January 17, 2017

It comes down to privacy—biomedical research can't proceed without human genomic data sharing, and genomic data sharing can't proceed without some reasonable level of assurance that de-identified data from patients and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.